Joe has a diverse scientific background and holds advanced degrees in biology, chemistry and computer science. He focuses his practice on patent drafting and prosecution, management and development of global patent portfolios, patentability and freedom-to-operate analysis, IP due diligence and licensing, post-grant and inter partes review proceedings, and IP litigation.

He has advised and interacted extensively with clients and inventors to evaluate the business value of inventions, to devise strategies for drafting U.S. and foreign patent applications, and to guide examination strategies before worldwide patent offices. He is also highly experienced in conducting competitive landscape and due diligence analyses and preparation of non-infringement, invalidity and freedom to operate analyses.

Formerly a research fellow at a Fortune 500 pharmaceutical company, Joe has more than a decade of experience in drug discovery and development in both academic and industrial settings. He directly contributed to multiple inventions of novel clinical candidates and played key roles in advancing three preclinical programs into clinical stages. The therapeutic areas that he has worked on include oncology, inflammation, cardiovascular, neuroscience, and infectious diseases. He is well-versed in medicinal chemistry, organic chemistry, nanomaterials, molecular biology, biochemistry, cell biology, immunology, neurology, and pharmacology. He also has extensive experience in pharmaceuticals, therapeutic protein engineering and production, antibody and vaccine development, and medical diagnostics.

With more than 10 years of drug discovery experience in his previous career and advanced degrees in computer science (M.S.), chemistry (M.S.) and biology (Ph.D.), Joe is in an excellent position to provide legal advice to clients in connection with their development of IP in artificial intelligence/machine learning areas within the life sciences, such as AI-based/structure-based drug design, AI-based image analysis, AI-based biomarker analysis for diagnosis and treatment, and AI-based human digital twin for personalized health care. He has also advised clients developing IP for non-life science AI-based applications, such as autonomous driving and facial recognition.

Additionally, he is experienced in drafting/reviewing licensing agreements, research collaboration agreements, clinical trial agreements, contract research or manufacturing agreements, master service agreements, share subscription agreements, shareholder agreements, non-disclosure agreements, etc.